Kyle Diamantas has held the acting FDA commissioner role since Marty Makary’s May 2026 resignation, giving him an edge through demonstrated leadership of the Human Foods Program and internal continuity. Competing names such as Brett Giroir and Stephen Hahn draw from prior Trump administration experience, while Sara Brenner and Grace Graham represent other regulatory backgrounds under consideration. Senate confirmation requirements and ongoing White House vetting have extended the process, supporting elevated odds on no formal announcement by year-end. Recent performance reports on Diamantas and shifting finalist lists keep the field competitive without a clear frontrunner emerging.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于凯尔·迪亚曼塔斯 13%
布雷特·吉鲁瓦尔 8.2%
萨拉·布伦纳 7.2%
斯蒂芬·哈恩 6.2%
$18,953 交易量
$18,953 交易量
2026-12-31
凯尔·迪亚曼塔斯
27%
斯蒂芬·哈恩
6%
布雷特·吉鲁瓦尔
8%
格蕾丝·格雷厄姆
4%
萨拉·布伦纳
7%
截至12月31日没有宣布
32%
凯尔·迪亚曼塔斯 13%
布雷特·吉鲁瓦尔 8.2%
萨拉·布伦纳 7.2%
斯蒂芬·哈恩 6.2%
$18,953 交易量
$18,953 交易量
2026-12-31
凯尔·迪亚曼塔斯
$6,163 交易量
27%
斯蒂芬·哈恩
$1,802 交易量
6%
布雷特·吉鲁瓦尔
$3,007 交易量
8%
格蕾丝·格雷厄姆
$4,151 交易量
4%
萨拉·布伦纳
$2,798 交易量
7%
截至12月31日没有宣布
$1,032 交易量
32%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Kyle Diamantas has held the acting FDA commissioner role since Marty Makary’s May 2026 resignation, giving him an edge through demonstrated leadership of the Human Foods Program and internal continuity. Competing names such as Brett Giroir and Stephen Hahn draw from prior Trump administration experience, while Sara Brenner and Grace Graham represent other regulatory backgrounds under consideration. Senate confirmation requirements and ongoing White House vetting have extended the process, supporting elevated odds on no formal announcement by year-end. Recent performance reports on Diamantas and shifting finalist lists keep the field competitive without a clear frontrunner emerging.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
市场开放时间： May 12, 2026, 7:59 PM ET
交易量
$18,953结束日期
2026-12-31市场开放时间
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Kyle Diamantas has held the acting FDA commissioner role since Marty Makary’s May 2026 resignation, giving him an edge through demonstrated leadership of the Human Foods Program and internal continuity. Competing names such as Brett Giroir and Stephen Hahn draw from prior Trump administration experience, while Sara Brenner and Grace Graham represent other regulatory backgrounds under consideration. Senate confirmation requirements and ongoing White House vetting have extended the process, supporting elevated odds on no formal announcement by year-end. Recent performance reports on Diamantas and shifting finalist lists keep the field competitive without a clear frontrunner emerging.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
交易量
$18,953结束日期
2026-12-31市场开放时间
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...Kyle Diamantas has held the acting FDA commissioner role since Marty Makary’s May 2026 resignation, giving him an edge through demonstrated leadership of the Human Foods Program and internal continuity. Competing names such as Brett Giroir and Stephen Hahn draw from prior Trump administration experience, while Sara Brenner and Grace Graham represent other regulatory backgrounds under consideration. Senate confirmation requirements and ongoing White House vetting have extended the process, supporting elevated odds on no formal announcement by year-end. Recent performance reports on Diamantas and shifting finalist lists keep the field competitive without a clear frontrunner emerging.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题